Compare EPM & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | EOLS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 444.0M |
| IPO Year | 1996 | 2018 |
| Metric | EPM | EOLS |
|---|---|---|
| Price | $4.07 | $6.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.75 | ★ $20.80 |
| AVG Volume (30 Days) | 404.6K | ★ 1.1M |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | ★ 11.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $85,232,000.00 | ★ $285,823,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | $2.97 | $23.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.10 |
| 52 Week Low | $3.71 | $5.71 |
| 52 Week High | $5.70 | $17.12 |
| Indicator | EPM | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 52.83 |
| Support Level | $4.02 | $6.83 |
| Resistance Level | $4.27 | $7.29 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 62.00 | 68.82 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.